RGCC Southeast Asia

RGCC Southeast Asia About Research Genetic Cancer Centre
RGCC is a specialist medical genetics company, established in 2004 with headquarters in Switzerland.

We are experts in developing and providing personalised cancer genetics tests for doctors and patients, and testing tumours for sensitivity and resistance to chemotherapy treatment and a range of natural substances. We are actively involved in pharmaceutical research and development. Our facilities are equipped with the most technologically advanced equipment and specialised software for data anal

ysis. RGCC is a global organisation, and we work in collaboration with branch offices and distributors to provide a worldwide service.

At , personalized medicine is at the heart of everything we do.As Dr. Ioannis Papasotiriou, our Founder and Director, ...
09/01/2026

At , personalized medicine is at the heart of everything we do.

As Dr. Ioannis Papasotiriou, our Founder and Director, says:
”Every human is not identical. Why should their be identical? Why should every person be treated in the same manner?“

This philosophy drives our dedication to tailor treatments that are as unique as each individual we serve.

31/12/2025

As 2025 comes to a close, we extend our heartfelt gratitude to our partners, clinicians, and patients around the world. May your holidays be filled with peace, health, and hope for the year ahead. ✨ Happy Holidays from all of us at RGCC.

🎉 Reflecting on a remarkable 2025 at RGCC!As 2025 draws to a close, we take a moment to reflect on a year marked by scie...
19/12/2025

🎉 Reflecting on a remarkable 2025 at RGCC!

As 2025 draws to a close, we take a moment to reflect on a year marked by scientific progress, collaboration, and continued commitment to advancing personalized oncology.

This year, strengthened its global presence through international gatherings, scientific conferences, and collaborative research initiatives that united leading oncologists, healthcare practitioners, and researchers from around the world. We also celebrated important milestones, including the launch of the InVyomma Plus test.

As we look ahead to 2026, we remain dedicated to expanding the frontiers of precision medicine and supporting clinicians in providing truly personalized cancer care.

Our Oncotrace test is a powerful monitoring tool designed to assess progression. Through a simple blood draw, Oncotrac...
09/12/2025

Our Oncotrace test is a powerful monitoring tool designed to assess progression. Through a simple blood draw, Oncotrace detects and analyzes circulating cells (CTCs), evaluating their presence, enumeration, and immunophenotype. This information helps determine how advanced the cancer is and the potential for metastatic spread.

By tracking CTC dynamics over time, Oncotrace enables physicians to monitor disease progression, evaluate treatment effectiveness, and make informed decisions about therapeutic strategies.

Address

RGCC Global Ltd, Suite 1701-02, 17/F, FWD Financial Centre, 308 Des Voeux Road Central
Hong Kong

Website

Alerts

Be the first to know and let us send you an email when RGCC Southeast Asia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category